1. Home
  2. BMEA vs FUSB Comparison

BMEA vs FUSB Comparison

Compare BMEA & FUSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.35

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

HOLD

Current Price

$14.97

Market Cap

84.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
FUSB
Founded
2017
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
90.5M
84.4M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
BMEA
FUSB
Price
$1.35
$14.97
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$8.71
N/A
AVG Volume (30 Days)
771.9K
6.9K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
N/A
1.87%
EPS Growth
N/A
N/A
EPS
N/A
1.00
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$23.44
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$10.47
52 Week High
$3.08
$15.99

Technical Indicators

Market Signals
Indicator
BMEA
FUSB
Relative Strength Index (RSI) 49.64 49.45
Support Level $1.24 $14.70
Resistance Level $1.43 $15.49
Average True Range (ATR) 0.10 0.21
MACD 0.00 -0.05
Stochastic Oscillator 38.89 34.18

Price Performance

Historical Comparison
BMEA
FUSB

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

Share on Social Networks: